BreakingApprovals

Etcamah's Sept 4 Approval Does Not Rewrite Orserdu PAs or ODAC's ctDNA Dispute

FDA granted accelerated approval to camizestrant (Etcamah) on Sept 4, 2026. We analyze SERENA-6 PFS, ODAC's 3-6 vote, live Orserdu/Veppanu SPLs, and FEP PAs.

PHOTO ILLUSTRATION · PHARMADOSSIER

By Ran Chen·Updated September 5, 2026·29 min read

Latest in biopharma

Lirafugratinib's Sept 27 PDUFA Does Not Rewrite Pemazyre PAs or Lytgobi CDx

By Ran Chen#PDUFA Date #FDA Approval #NDA Approval

Approvals· September 3, 2026 · 34 min read

Injectafer's Phosphate Boxed Warning Does Not Rewrite J1439, AP Generics, or Oral-Iron PAs

By Ran Chen#Boxed Warning #Label Warnings #FDA Approval

Approvals· September 2, 2026 · 33 min read

Aqneursa's Sept 19 A-T PDUFA Does Not Rewrite NPC-Only PAs or the 15 kg Floor

By Ran Chen#PDUFA Date #FDA Approval #NDA Approval

Approvals· September 1, 2026 · 29 min read

Camzyos's Sept 30 Adolescent PDUFA Does Not Rewrite Adult REMS or Age-18 PA Gates

By Ran Chen#PDUFA Date #FDA Approval #NDA Approval

Policy· August 31, 2026 · 16 min read

CMS Part D 340B Repository: Voluntary Files Do Not Replace Prescriber Math

By Ran Chen#340B #Medicare Part D #IRA Negotiation

Policy· August 31, 2026 · 18 min read

CMS RAPID Is an IDE Presubmission NCD Clock, Not Post-Authorization Coverage

By Ran Chen#Coverage Access #Payer Policy #Medicare Part B

Specialty· August 31, 2026 · 36 min read

Generic Erleada (Apalutamide): U.S. Entry, Patents, and Launch Signals

By Ran Chen#Oncology #Generic Entry #Orange Book

The PharmaDossier Daily

The eight-minute biopharma briefing for access, regulatory, and commercial teams.

Launch signals, payer moves, biosimilar reads, and FDA source links every weekday.

Browse topics

Sections

Topic watch

Coverage Access171 Prior Authorization169 Payer Policy149 FDA Approval147 Specialty Pharmacy88 Formulary Strategy79 Specialty Drugs76 Oncology74 Clinical Evidence72 GLP-167 Drug Pricing66 Biosimilars65 Orange Book65 Market Access60

Editorial standard

Every article links back to FDA, CMS, DailyMed, Purple Book, Orange Book, ClinicalTrials.gov, or another primary source wherever the claim depends on regulated status.

Lead editor: Founder, PharmaDossier. Life-sciences operator covering market access, specialty pharma, biosimilars, and regulated healthcare growth.